



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Case No. C-3405/US (MBHB Ref. No. 01-677)

In the Application of:

Hageman et al.

Group Art Unit: 1626

Serial No.: 09/730,663

Filed: December 6, 2000

**For: Solid State Form of Celecoxib Having
Enhanced Bioavailability**

RECEIVED

FEB 27 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
Washington, D.C. 20231

Dear Sir:


This prior art statement is filed under 37 C.F.R. §§1.97-1.98 in compliance with the duty of disclosure set forth in 37 C.F.R. §1.56.

In the judgment of the undersigned, the references listed on the attached Form PTO-1449 may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this statement or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102.

U.S. PATENT DOCUMENT

1. U.S. Patent No. 5,466,823, published November 14, 1995.
2. U.S. Patent No. 5,892,053, published April 6, 1999.

02.11.02 CHM: 000002 0973053



COPY OF PAPERS
ORIGINALLY FILED

FOREIGN PATENT DOCUMENTS

3. WO 00/42021, published July 20, 2000.

OTHER DOCUMENTS

4. Lieberman, et al. (1989) Pharmaceutical Dosage Forms: Tablets. Vol. 1, pp. 34-36

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Respectfully submitted
McDONNELL BOEHNEN
HULBERT & BERGHOFF
300 South Wacker Drive, 32nd Floor
Chicago, Illinois 60606
Tel: (312) 913-0001
Fax: (312) 913-0002

Dated: October 19, 2001

By: Raef Shaltout
Raef Shaltout
Reg. No. 45,092

COPIES OF PAPERS
ORIGINALLY FILED

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Case No. C-3405/1/US (MBHB Ref. No. 01-677)

In the Application of:

Hageman et al.

Serial No.: 09/730,663

Filed: December 6, 2000

For: Solid State Form of Celecoxib Having
Enhanced Bioavailability

)
)
)
)
)
)
)

Group Art Unit: 1626

RECEIVED

FEB 27 2002

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached Information Disclosure Statement and PTO Form 1449 including four (4) cited references.
2. With respect to additional fees:
 - A. Attached is a check in the amount of \$180.00.
 - B. The Commissioner is hereby authorized to charge the amount to Deposit Account No. 13-2490.
- 3 Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
4. CERTIFICATE OF TRANSMISSION UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being sent with sufficient postage as first class mail to the Patent and Trademark Office on this 19th October 2001.

By:

Raef Shaltout

Raef Shaltout
Reg. No. 45,092